{"id":"W4308349064","doi":"10.1016/s2213-2600(22)00434-9","title":"Discontinuation versus continuation of hypertonic saline or dornase alfa in modulator treated people with cystic fibrosis (SIMPLIFY): results from two parallel, multicentre, open-label, randomised, controlled, non-inferiority trials","year":2022,"lang":"en","type":"article","venue":"The Lancet Respiratory Medicine","topic":"Cystic Fibrosis Research Advances","field":"Medicine","cited_by":126,"is_retracted":false,"has_abstract":false,"ca_institutions":"Hospital for Sick Children","funders":"National Center for Advancing Translational Sciences; National Institute of Diabetes and Digestive and Kidney Diseases; Chiesi USA; National Institutes of Health; Nabriva Therapeutics; Vertex Pharmaceuticals; Insmed; Gilead Sciences; Cystic Fibrosis Foundation; Genentech; AstraZeneca; GlaxoSmithKline; National Heart, Lung, and Blood Institute; American Thoracic Society","keywords":"Medicine; Hypertonic saline; Cystic fibrosis; Discontinuation; Randomized controlled trial; Ivacaftor; Clinical trial; Internal medicine; Physical therapy; Cystic fibrosis transmembrane conductance regulator","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002964778,0.001538504,0.004699255,0.0004616882,0.0004276116,0.001312538,0.0009979064,0.003003056,0.005346668],"category_scores_gemma":[0.006836855,0.0006626371,0.005566244,0.00056437,0.001526407,0.001549598,0.0006439399,0.003363451,0.0006957378],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0009183271,"about_ca_system_score_gemma":0.0008261533,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001291435,"about_ca_topic_score_gemma":0.001837665,"domain_scores_codex":[0.997565,0.001404665,0.0002575998,0.0003584178,0.0001671958,0.0002470836],"domain_scores_gemma":[0.9961277,0.002020014,0.0009519571,0.0002993861,0.0001792412,0.0004217807],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9847484,0.001083308,0.0004471657,0.00134153,0.002220099,0.00002422425,0.00006728214,0.00008929592,0.0006538711,0.00004892644,0.0001999736,0.009075838],"study_design_scores_gemma":[0.9685139,0.02691201,0.002006148,0.0001516287,0.001595316,0.00002675794,0.0000397688,0.0001063307,0.0001351187,0.0001633353,0.000332259,0.00001741783],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.963454,0.02861809,0.001053338,0.0010231,0.001045582,0.00229951,0.0008048465,0.00010246,0.00159897],"genre_scores_gemma":[0.9840294,0.007961072,0.001568682,0.001050934,0.0007478581,0.002341732,0.0007367139,0.00002841511,0.001535294],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.005346668,"threshold_uncertainty_score":0.01788634,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.1101472016697327,"score_gpt":0.3964294450731055,"score_spread":0.2862822434033727,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}